Question follow-through · 92553
General Practitioners: West Midlands
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase GP appointment availability in the West Midlands; and what assessment he has made of primary care staffing levels in Walsall.
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 19 Nov 2025
- Target answer date
- 24 Nov 2025
- Answer
- 26 Nov 2025 · 7 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
More questions by this MP on Health and care
- Health Hazards: Birmingham · 26 Nov 2025
- Independent Review into Mental Health Conditions, ADHD and Autism · 9 Dec 2025
- Independent Review into Mental Health Conditions, ADHD and Autism · 9 Dec 2025
- Independent Review into Mental Health Conditions, ADHD and Autism · 9 Dec 2025
- Independent Review into Mental Health Conditions, ADHD and Autism · 9 Dec 2025
Shared topic keywords suggest a connection; they do not establish a follow-up.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
19 Nov 2025
Question tabled
To ask the Secretary of State for Health and Social Care, what steps he is taking to increase GP appointment availability in the West Midlands; and what assessment he has made of primary care staffing levels in Walsall.
24 Nov 2025
Target answer date
Date supplied by the official written-questions record.
26 Nov 2025
Answer published
West Midlands sits within the Black Country Integrated Care Board (ICB) where appointment availability in general practice (GP) has increased by 13.8% in September 2025 compared to the same period last year. In October 2024, we invested £160 million into ...
Official data retrieved 28 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
Health Hazards: Birmingham
26 Nov 2025 · To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential public health risks arising from the withdrawal of waste collection services in Birmingham following the decision by agency refuse workers to take indus
Independent Review into Mental Health Conditions, ADHD and Autism
9 Dec 2025 · To ask the Secretary of State for Health and Social Care, with reference to the Written Statement entitled Mental Health Conditions, Autism and ADHD Prevalence and Support, published on 4 December 2025, HCWS1132, what assessment his Department has made of
Independent Review into Mental Health Conditions, ADHD and Autism
9 Dec 2025 · To ask the Secretary of State for Health and Social Care, with reference to the Written Statement entitled Mental Health Conditions, Autism and ADHD Prevalence and Support, published on 4 December 2025, HCWS1132, what assessment he has made of regional va
Independent Review into Mental Health Conditions, ADHD and Autism
9 Dec 2025 · To ask the Secretary of State for Health and Social Care, with reference to the Written Statement entitled Mental Health Conditions, Autism and ADHD Prevalence and Support, published on 4 December 2025, HCWS1132, what assessment his Department has made of
Independent Review into Mental Health Conditions, ADHD and Autism
9 Dec 2025 · To ask the Secretary of State for Health and Social Care, with reference to the Written Statement entitled Mental Health Conditions, Autism and ADHD Prevalence and Support, published on 4 December 2025, HCWS1132, what criteria will be used to appoint memb
Community Health Services: West Midlands
22 Jan 2026 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 November 2025 to Question 90706, what funding has been allocated to each West Midlands area participating in wave 1 of the National Neighbourhood Health Implementation
Community Health Services: West Midlands
22 Jan 2026 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 November 2025 to Question 90706, how neighbourhood health services in the West Midlands will be staffed in practice; what steps are being taken to address workforce sho
Community Health Services: West Midlands
22 Jan 2026 · To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 November 2025 to Question 90706, how the Neighbourhood Health Service will improve access to care in rural areas and communities with poor digital connectivity or low d
Prostate Cancer: Abiraterone
28 Jan 2026 · To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, how many patients with non-metastatic prostate cancer are expected to be eligible for abiraterone in each of the next three financial years; what clinical criteria deter
Prostate Cancer: Medical Treatments
28 Jan 2026 · To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what assessment has been made of existing regional variation in access to prostate cancer treatments and what steps are being taken to prevent disparities in uptake betw
Prostate Cancer: Abiraterone
28 Jan 2026 · To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what estimate has been made of the annual cost to the NHS of expanding access to abiraterone; what savings have been achieved through the availability of generic version
Prostate Cancer: Abiraterone
28 Jan 2026 · To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what arrangements are in place to monitor patient outcomes following the expanded use of abiraterone at earlier stages of prostate cancer; and whether those outcomes wil